Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 5, 2011, Pages 373-379

  Charpentier, Charlotte ^a,b   Jenabian, Mohammad Ali ^b   Piketty, Christophe ^a   Karmochkine, Marina ^a   Tisserand, Pascaline ^a   Laureillard, Didier ^a   Bélec, Laurent ^a,b   Si Mohamed, Ali ^a   Weiss, Laurence ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

archiving; enfuvirtide; HIV; resistance

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; VIRUS DNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; SALVAGE THERAPY; VIRUS LOAD; VIRUS MUTATION;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRAL LOAD;

EID: 79954556654     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.552520     Document Type: Article

References (26)

1. Lalezari JP, Henry K, O' H earn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. (Pubitemid 36618128)
2. Lazzarin A, Clotet B, Cooper D, Reynes J, Arast é h K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95. (Pubitemid 36618129)
3. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93. (Pubitemid 28116876)
4. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-94. (Pubitemid 39179630)
5. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905. (Pubitemid 34535213)
6. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardi è re JL, Pacanowski J, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80:8807-19. (Pubitemid 44384889)
7. Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60-4. (Pubitemid 44306489)
8. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonz á lez-Lahoz J, et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004; 74:21-8. (Pubitemid 38988855)
9. Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, et al. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J Med Virol 2006;78:1312-7. (Pubitemid 44387517)
10. Marcelin AG, Reynes J, Yerly S, Ktorza N, Segondy M, Piot JC, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004;18:1340-2. (Pubitemid 38822715)
11. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005;34:295-301. (Pubitemid 41605446)
12. Aquaro S, D' A rrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;5:714-22. (Pubitemid 44390943)
13. Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195:387-91. (Pubitemid 46146116)
14. Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide. AIDS 2002;16:1603-8.
15. Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, et al. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr 2007;44:1-5. (Pubitemid 46052213)
16. Thompson JD, Higgins DG, Gibson TJ. Clustal W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80. (Pubitemid 24354800)
17. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrugresistant HIV-1 infection. J Infect Dis 2005;192:1537-44. (Pubitemid 41504689)
18. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005;410:236-42. (Pubitemid 40962506)
19. Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004;37:1581-3. (Pubitemid 39658197)
20. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70.
21. Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007;23: 1078-82. (Pubitemid 47571945)
22. Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, et al. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic Syndr 2008;48:572-6.
23. Cabrera C, Marfi lS, Garcia E, Martinez-Picado J, Bonjoch A, Bofill M, et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 2006;20:2075-80. (Pubitemid 44611060)
24. Trabaud MA, Cotte L, Labernardiere JL, Lebel-Binay S, Icard V, Tardy JC, et al. Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr 2007;46:34-44.
25. Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, et al. Virological fitness of HIV in patients with resistance to enfuvirtide. AIDS 2007;21:1974 - 7. (Pubitemid 47329777)
26. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004;48:3253-9. (Pubitemid 39129315)